Reference Ranges for Left Modified Myocardial Performance Index: Systematic Review and Meta-Analysis
Fetal Diagnosis and Therapy · 2024
DOI: 10.1159/000535602 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Fetal Diagnosis and Therapy, 2024. Verfasst von Katherine H Bligard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Fetal Heart, Ultrasonography, Prenatal. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The modified myocardial performance index (mod-MPI) is a noninvasive Doppler-derived metric used to evaluate fetal cardiac function. However, the reference ranges for mod-MPI in normal fetuses are not clearly defined, which limits the use of this technology in fetuses with potential cardiac compromise. Thus, we aimed to perform a systematic review and meta-analysis of published mod-MPI reference ranges across gestation.
Methods
The published literature was systematically searched, and all published articles in any language that provided values for the left ventricular mod-MPI obtained in low-risk, singleton fetuses were considered eligible for further review. All retrieved titles and abstracts were independently reviewed by two researchers. Mean and standard deviation by gestational week was extracted or calculated from published data. DerSimonian-Laird random-effects models were used to estimate pooled means and 95% confidence intervals (CIs).
Results
The search resulted in 618 unique citations, of which 583 did not meet inclusion criteria, leaving 35 abstracts selected for full-text review. Review of the references of these 35 articles identified another 5 studies of interest. Of the 40 articles reviewed, six met inclusion criteria. There was significant heterogeneity seen in the mod-MPI results reported. Mod-MPI increased as pregnancy progressed in all studies. The pooled mean mod-MPI at 11 weeks’ gestation was 0.400 (95% CI 0.374–0.426) and increased to 0.585 (95% CI 0.533–0.637) at 41 weeks’ gestation. The increase was linear in 5 of 6 studies, while in 1 study, the mod-MPI was stable until 27 weeks’ gestation, and then increased throughout the third trimester. Despite all having trends increasing over pregnancy, there was no study in which all the weekly means fell within the pooled 95% CI.
Conclusion
While mod-MPI does increase over gestation, the true “reference ranges” for fetuses remain elusive. Future efforts to further optimize calculation of time intervals possibly via automation are desperately needed to allow for reproducibility of this potentially very useful tool to assess fetal cardiac function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
- Bernard Becker Medical Library, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
- Department of Obstetrics and Gynecology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Zitieren
APA
Bligard, K. H., Doering, M., Porat, S., & Rosenbloom, J. I. (2024). Reference Ranges for Left Modified Myocardial Performance Index: Systematic Review and Meta-Analysis. Fetal Diagnosis and Therapy. https://doi.org/10.1159/000535602
Vancouver
Bligard KH, Doering M, Porat S, Rosenbloom JI. Reference Ranges for Left Modified Myocardial Performance Index: Systematic Review and Meta-Analysis. Fetal Diagnosis and Therapy. 2024. doi:10.1159/000535602
BibTeX
@article{Bligard2024,
author = {Bligard, Katherine H and Doering, Michelle and Porat, Shay and Rosenbloom, Joshua I},
title = {Reference Ranges for Left Modified Myocardial Performance Index: Systematic Review and Meta-Analysis},
journal = {Fetal Diagnosis and Therapy},
year = {2024},
doi = {10.1159/000535602}
}
EUVIMED